MedTrace Logo

Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

NCT00549614 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2009-10-07

No results posted yet for this study

Summary

The primary objective of this study is to evaluate whether metabolic modulation improves left ventricular function, work capacity, insulin sensitivity and modifies substrate metabolism in chronic heart failure

Conditions

Interventions

DRUG

acipimox

capsule, 250 mg, 4 times daily for 28 days

DRUG

placebo

capsule, 250 mg, 4 times daily for 28 days

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Mads Halbirk · B-research, Aarhus Universityhospital, skejby

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-12-31
Completion
2009-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00549614 on ClinicalTrials.gov